Again, the results from the Phase 1a trial were from a 4th line of treatment. Those patients had had the three previous trials fail them. The trial you refer to has the drug as the second line of treatment, surgery being the first. So you cant compare these results as the wellness of the patient cohort are not compatible. The patients from the CHM trial would have been excluded from the trial you refer to.
The only real comparison is the Phase 1a trial results to those drugs that the FDA has already approved for GBM. Shell has posted the chart showing that comparison, and the announcement shows the increase in mean survivability. And that is comparing a 4th line treatment to a second line treatment drug, one of which is mentioned in that trial you mentioned.
We hope the phase 1b replicates or betters the phase 1a results. Time will tell.
And then there are the other drugs and trials. As I have said before. I dont see any other biotech companies on the asx with as much potential bang for buck as CHM at the moment. Still high risk, but potential for very high reward counters some of that. Total IP value under $5million aud atm. For this diverse pipeline that is incredibly cheap.
CHM Price at posting:
2.6¢ Sentiment: Buy Disclosure: Held
